Dr. Lizzie Lim

Medical Oncologist with a passion for leading early phase oncology clinical trials, including first-in-human studies. Specialized expertise in neuro-oncology, head and neck, and upper GI tumours. Proven track record as an investigator for more 30 than phase 1 trials. Worked in a team to start and establish decentralized phase 1 trials, along with the only first-in-human trials in regional Victoria.

Omico scientific advisory committee member and site representative.

Victorian Rare Cancer Clinical Trial Alliance site representative.

• Pavlakis N, Tincknell G, Lim LE et al., European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions., Ther Adv Med Oncol, 2022, 14
• Kwan EM…Lim LE et al., Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer., Transl Androl Urol., 04/01/21, 10(4), 1688-1699
• Lim LE, Chan DL, Thomas D, Du Y, Tincknell G, Kuchel A, et al., Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours., Oncotarget., 2020, 11(27)
• Lim LE, Huggins M, Faisal W, Wuttke M, Chong G., Survival outcomes for patients with early stage colorectal cancer in a regional centre compared to a metropolitan centre in Victoria., AJRH., 2020
• Lim LE, Dowdle B, Gardiner D., An unexpected joint infection., IDH., 05/01/17
• Lim LE, Wright C., Nephrotic syndrome., HEAL., 01/01/13
• Lim LE, Wright C., Microcytic anaemias, including iron deficiency., HEAL., 01/01/13

• An Australian multi-centre experience of the use of peptide receptor radionuclide therapy for bronchial carcinoid tumours, 09/27/19 - 10/01/19, ESMO World Congress
• Mortality in early stage colorectal cancer: A comparative analysis between a regional and metropolitan centre in Victoria, 11/12/18 - 11/14/18, Clinical Oncology Society of Australia (COSA) ASM
• Causes of death in a cohort of early stage colorectal cancer patients at a regional centre in Australia, 06/20/18 - 06/23/18, World Gastrointestinal Cancer Conference
• PAPP-A is a marker of aggressive breast cancer and promotes cancer progression in vitro, 11/17/17 - 11/19/17, ESMO Asia Congress
• Neutrophil to Lymphocyte Ratio (NLR) as an independent prognostic measure in patients receiving targeted therapy or immunotherapy for stage IV melanoma, 09/08/17 - 09/11/17, European Society of Medical Oncology (ESMO) Congress
• Neutrophil to Lymphocyte Ratio (NLR) as an independent prognostic measure in patients receiving targeted therapy or immunotherapy for stage IV melanoma, 08/02/17 - 08/04/17, Medical Oncology Group of Australia (MOGA) ASM, Plenary session
• Breast cancer management and outcomes in Regional Victoria, 11/17/15 - 11/19/15, Clinical Oncology Society of Australia (COSA) ASM, Poster, 1st author
• Breast cancer outcomes in Greater Shepparton, 05/11/15 - 05/12/15, Victorian Integrated Cancer Service Conference

The Royal Australasian College of Physicians

FRACP - Medical Oncology

Monash University

MBBS (Honours) - Medicine